MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 637 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 1.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 41,442 shares of the company’s stock after purchasing an additional 637 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of Akero Therapeutics worth $1,153,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Sterling Capital Management LLC increased its position in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after acquiring an additional 1,582 shares in the last quarter. Quarry LP acquired a new position in Akero Therapeutics in the 4th quarter worth $83,000. Summit Investment Advisors Inc. increased its holdings in Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Akero Therapeutics by 8.5% in the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock valued at $220,000 after purchasing an additional 621 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock valued at $227,000 after purchasing an additional 8,147 shares in the last quarter.

Insider Activity at Akero Therapeutics

In related news, VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $48.09, for a total value of $48,090.00. Following the transaction, the vice president now directly owns 33,492 shares in the company, valued at approximately $1,610,630.28. This represents a 2.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO William Richard White sold 676 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $30,338.88. Following the transaction, the chief financial officer now directly owns 61,959 shares in the company, valued at approximately $2,780,719.92. This represents a 1.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 223,208 shares of company stock worth $9,313,294. Company insiders own 7.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AKRO. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Citigroup lowered their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Canaccord Genuity Group raised their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $82.33.

Akero Therapeutics Price Performance

Shares of AKRO opened at $46.36 on Monday. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $40.97 and its 200 day simple moving average is $38.31. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -12.36 and a beta of -0.12.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.